For research use only. Not for therapeutic Use.
(±)-SLV319 is the racemate of SLV319. SLV319 is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
Catalog Number | I013658 |
CAS Number | 362519-49-1 |
Molecular Formula | C₂₃H₂₀Cl₂N₄O₂S |
Purity | ≥95% |
Target | Cannabinoid Receptor |
Solubility | DMSO: ≥ 31 mg/mL |
IUPAC Name | 5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N//'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide |
InChI | InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28) |
InChIKey | AXJQVVLKUYCICH-UHFFFAOYSA-N |
SMILES | CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
Reference | [1]. Chorvat RJ, et al. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80. <br>[2]. Lange JH, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47(3):627-43.<br>[3]. Rohrbach K, et al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14(6):555-64. |